Cargando…
Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules
BACKGROUND: Stereotactic body radiotherapy (SBRT) is evolving into a standard of care for unresectable lung nodules. Local control has been shown to be in excess of 90% at 3 years. However, some patients present with synchronous lung nodules in the ipsilateral or contralateral lobe or metasynchronou...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341868/ https://www.ncbi.nlm.nih.gov/pubmed/25889747 http://dx.doi.org/10.1186/s13014-015-0340-9 |
_version_ | 1782359215686287360 |
---|---|
author | Owen, Dawn Olivier, Kenneth R Mayo, Charles S Miller, Robert C Nelson, Kathryn Bauer, Heather Brown, Paul D Park, Sean S Ma, Daniel J Garces, Yolanda I |
author_facet | Owen, Dawn Olivier, Kenneth R Mayo, Charles S Miller, Robert C Nelson, Kathryn Bauer, Heather Brown, Paul D Park, Sean S Ma, Daniel J Garces, Yolanda I |
author_sort | Owen, Dawn |
collection | PubMed |
description | BACKGROUND: Stereotactic body radiotherapy (SBRT) is evolving into a standard of care for unresectable lung nodules. Local control has been shown to be in excess of 90% at 3 years. However, some patients present with synchronous lung nodules in the ipsilateral or contralateral lobe or metasynchronous disease. In these cases, patients may receive multiple courses of lung SBRT or a single course for synchronous nodules. The toxicity of such treatment is currently unknown. METHODS: Between 2006 and 2012, 63 subjects with 128 metasynchronous and synchronous lung nodules were treated at the Mayo Clinic with SBRT. Demographic patient data and dosimetric data regarding SBRT treatments were collected. Acute toxicity (defined as toxicity < 90 days) and late toxicity (defined as toxicity > = 90 days) were reported and graded as per standardized CTCAE 4.0 criteria. Local control, progression free survival and overall survival were also described. RESULTS: The median age of patients treated was 73 years. Sixty five percent were primary or recurrent lung cancers with the remainder metastatic lung nodules of varying histologies. Of 63 patients, 18 had prior high dose external beam radiation to the mediastinum or chest. Dose and fractionation varied but the most common prescriptions were 48 Gy/4 fractions, 54 Gy/3 fractions, and 50 Gy/5 fractions. Only 6 patients demonstrated local recurrence. With a median follow up of 12.6 months, median SBRT specific overall survival and progression free survival were 35.7 months and 10.7 months respectively. Fifty one percent (32/63 patients) experienced acute toxicity, predominantly grade 1 and 2 fatigue. One patient developed acute grade 3 radiation pneumonitis at 75 days. Forty six percent (29/63 patients) developed late effects. Most were grade 1 dyspnea. There was one patient with grade 5 pneumonitis. CONCLUSION: Multiple courses of SBRT and SBRT delivery after external beam radiotherapy appear to be feasible and safe. Most toxicity was grade 1 and 2 but the risk was approximately 50% for both acute and late effects. |
format | Online Article Text |
id | pubmed-4341868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43418682015-02-27 Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules Owen, Dawn Olivier, Kenneth R Mayo, Charles S Miller, Robert C Nelson, Kathryn Bauer, Heather Brown, Paul D Park, Sean S Ma, Daniel J Garces, Yolanda I Radiat Oncol Research BACKGROUND: Stereotactic body radiotherapy (SBRT) is evolving into a standard of care for unresectable lung nodules. Local control has been shown to be in excess of 90% at 3 years. However, some patients present with synchronous lung nodules in the ipsilateral or contralateral lobe or metasynchronous disease. In these cases, patients may receive multiple courses of lung SBRT or a single course for synchronous nodules. The toxicity of such treatment is currently unknown. METHODS: Between 2006 and 2012, 63 subjects with 128 metasynchronous and synchronous lung nodules were treated at the Mayo Clinic with SBRT. Demographic patient data and dosimetric data regarding SBRT treatments were collected. Acute toxicity (defined as toxicity < 90 days) and late toxicity (defined as toxicity > = 90 days) were reported and graded as per standardized CTCAE 4.0 criteria. Local control, progression free survival and overall survival were also described. RESULTS: The median age of patients treated was 73 years. Sixty five percent were primary or recurrent lung cancers with the remainder metastatic lung nodules of varying histologies. Of 63 patients, 18 had prior high dose external beam radiation to the mediastinum or chest. Dose and fractionation varied but the most common prescriptions were 48 Gy/4 fractions, 54 Gy/3 fractions, and 50 Gy/5 fractions. Only 6 patients demonstrated local recurrence. With a median follow up of 12.6 months, median SBRT specific overall survival and progression free survival were 35.7 months and 10.7 months respectively. Fifty one percent (32/63 patients) experienced acute toxicity, predominantly grade 1 and 2 fatigue. One patient developed acute grade 3 radiation pneumonitis at 75 days. Forty six percent (29/63 patients) developed late effects. Most were grade 1 dyspnea. There was one patient with grade 5 pneumonitis. CONCLUSION: Multiple courses of SBRT and SBRT delivery after external beam radiotherapy appear to be feasible and safe. Most toxicity was grade 1 and 2 but the risk was approximately 50% for both acute and late effects. BioMed Central 2015-02-18 /pmc/articles/PMC4341868/ /pubmed/25889747 http://dx.doi.org/10.1186/s13014-015-0340-9 Text en © Owen et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Owen, Dawn Olivier, Kenneth R Mayo, Charles S Miller, Robert C Nelson, Kathryn Bauer, Heather Brown, Paul D Park, Sean S Ma, Daniel J Garces, Yolanda I Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules |
title | Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules |
title_full | Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules |
title_fullStr | Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules |
title_full_unstemmed | Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules |
title_short | Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules |
title_sort | outcomes of stereotactic body radiotherapy (sbrt) treatment of multiple synchronous and recurrent lung nodules |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341868/ https://www.ncbi.nlm.nih.gov/pubmed/25889747 http://dx.doi.org/10.1186/s13014-015-0340-9 |
work_keys_str_mv | AT owendawn outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT olivierkennethr outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT mayocharless outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT millerrobertc outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT nelsonkathryn outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT bauerheather outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT brownpauld outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT parkseans outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT madanielj outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules AT garcesyolandai outcomesofstereotacticbodyradiotherapysbrttreatmentofmultiplesynchronousandrecurrentlungnodules |